151 related articles for article (PubMed ID: 3337907)
21. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
[TBL] [Abstract][Full Text] [Related]
22. Correlations between karyotype and cytologic findings in multiple myeloma.
Weh HJ; Bartl R; Seeger D; Selbach J; Kuse R; Hossfeld DK
Leukemia; 1995 Dec; 9(12):2119-22. PubMed ID: 8609726
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a novel myeloma cell line, MM.1.
Goldman-Leikin RE; Salwen HR; Herst CV; Variakojis D; Bian ML; Le Beau MM; Selvanayagan P; Marder R; Anderson R; Weitzman S
J Lab Clin Med; 1989 Mar; 113(3):335-45. PubMed ID: 2926241
[TBL] [Abstract][Full Text] [Related]
24. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
25. Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.
Clark RE; Geddes AD; Whittaker JA; Jacobs A
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1789-93. PubMed ID: 2632260
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma with monosomy 13 developed in trisomy 13 acute myelocytic leukemia: numerical chromosome abnormality during chromosomal segregation process.
Sashida G; Ito Y; Nakajima A; Kawakubo K; Kuriyama Y; Yagasaki F; Bessho M; Ohyashiki K
Cancer Genet Cytogenet; 2003 Mar; 141(2):154-6. PubMed ID: 12606134
[TBL] [Abstract][Full Text] [Related]
27. High incidence of chromosome abnormalities in IgG3 myeloma.
Van den Berghe H; Vermaelen K; Louwagie A; Criel A; Mecucci C; Vaerman JP
Cancer Genet Cytogenet; 1984 Apr; 11(4):381-7. PubMed ID: 6704939
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of clinical features of multiple myeloma with t(8;14)(q24;q32)].
He Q; Duan WB; Wen L; Liu Y; Ma L; Wang FR; Huang XJ; Lu J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2363-2367. PubMed ID: 35970795
[No Abstract] [Full Text] [Related]
29. Chromosomes in plasma-cell malignancies.
Van Den Berghe H
Eur J Haematol Suppl; 1989; 51():47-51. PubMed ID: 2697595
[TBL] [Abstract][Full Text] [Related]
30. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
31. Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by cIg FISH.
White JS; Zordan A; Batzios C; Campbell LJ
Cancer Genet; 2012 Dec; 205(12):644-52. PubMed ID: 23200818
[TBL] [Abstract][Full Text] [Related]
32. [Nuclear lobulation in the plasma cells of a patient with multiple myeloma (Bence Jones type)].
Fujii H; Maekawa T; Nishida K; Urata Y
Rinsho Ketsueki; 1988 Nov; 29(11):2086-90. PubMed ID: 3236416
[No Abstract] [Full Text] [Related]
33. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia.
Lloveras E; Granada I; Zamora L; Espinet B; Florensa L; Besses C; Xandri M; Pérez-Vila ME; Millà F; Woessner S; Solé F
Cancer Genet Cytogenet; 2004 Jan; 148(1):71-6. PubMed ID: 14697644
[TBL] [Abstract][Full Text] [Related]
34. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetic and biological characterization of two new human plasma cell lines.
Brox LW; Belch A; Pollock E; He XX; De Braekeleer M; Lin CC
Cancer Genet Cytogenet; 1987 Jul; 27(1):135-44. PubMed ID: 3472643
[TBL] [Abstract][Full Text] [Related]
36. Karyotypic abnormalities and their clinical aspects in multiple myeloma.
Scudla V; Jarosová M; Kapustová M; Indrák K; Smoldas J
Acta Univ Palacki Olomuc Fac Med; 1991; 129():69-79. PubMed ID: 1837676
[TBL] [Abstract][Full Text] [Related]
37. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
38. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
Schilling G; Dierlamm J; Hossfeld DK
Hematol Oncol; 2005; 23(3-4):102-7. PubMed ID: 16342296
[TBL] [Abstract][Full Text] [Related]
40. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
